Korean Pharma Taking To Open Innovation In Diverse Ways
Executive Summary
The South Korean biopharma sector is adopting new approaches to beef up original R&D including open innovation, with Hanmi and LegoChem both recently setting up new operations to pursue collaborations as they look to expand internationally.
You may also be interested in...
Venture Funding Deals: Cell Medica Raises $73.2m, Tango Dances In With $55m
Novel approaches to infectious diseases and cancer garnered significant VC cash in recent months, including monoclonal antibodies to treat and prevent S. aureus, Cell Medica's next-generation T cell therapies and Tango's platform focused on genetic drivers of cancer.
New Korea Fund To Nurture Early Stage Biotech Start-Ups
South Korea is broadening its state support for the biotech industry, which it sees as a new growth engine, this time by focusing on early stage biotech start-ups, amid industry views that such support and investment in the country has so far been lacking.
Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal
After a series of blockbuster licensing deals last year, South Korea’s Hanmi has struck another major alliance, this time licensing out a novel oral RAF inhibitor that will strengthen biosimilar-threatened Genentech’s oncology portfolio.